By CIA, 94/244 (38.5%) of PSC patients [82/222 (36.9%) PSC, 12/22 (54.5%) AIH-PSC] were positive for PR3-ANCA compared to 27/254 (10.6%) of controls (p<0.0001). This evidence concerns the gene PRTN3 and pancreatic serous cystadenoma.